We are live on ! Find out more
ENTA icon

Enanta Pharmaceuticals
ENTA

124 hedge funds and large institutions have $549M invested in Enanta Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 36 increasing their positions, 42 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 21

35% more capital invested

Capital invested by funds: $408M → $549M (+$141M)

12% more funds holding

Funds holding: 111 → 124 (+13)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

14% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 42

62% less call options, than puts

Call options by funds: $1.13M | Put options by funds: $2.97M

Holders
124
Holders Change
+13
Holders Change %
+11.71%
% of All Funds
3.31%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
35
Increased
36
Reduced
42
Closed
21
Calls
$1.13M
Puts
$2.97M
Net Calls
-$1.84M
Net Calls Change
-$857K

Top Buyers

1
ACM
Apex Capital Management
Ohio
+$24M
2
State Street
State Street
Massachusetts
+$17.8M
3
BFA
BlackRock Fund Advisors
California
+$11.5M
4
EAM
Eagle Asset Management
Florida
+$8.23M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$5.67M

Top Sellers

1
SAM
Senzar Asset Management
New York
-$23.4M
2
RCM
RA Capital Management
Massachusetts
-$9.89M
3
GC
Guggenheim Capital
Illinois
-$7.39M
4
Marshall Wace
Marshall Wace
United Kingdom
-$5.45M
5
NI
Numeric Investors
Massachusetts
-$4.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$109M +$5.67M +126,750 +6%
CCM
2
Consonance Capital Management
New York
$86.2M +$4.34M +97,038 +6%
EAM
3
Eagle Asset Management
Florida
$56.4M +$8.23M +183,771 +20%
ACM
4
Apex Capital Management
Ohio
$29.8M +$24M +536,451 +1,068%
State Street
5
State Street
Massachusetts
$26.5M +$17.8M +397,077 +318%
BFA
6
BlackRock Fund Advisors
California
$25.8M +$11.5M +257,293 +103%
GT
7
Glenmede Trust
Pennsylvania
$20.8M +$3.62M +80,821 +25%
Vanguard Group
8
Vanguard Group
Pennsylvania
$13.4M +$949K +21,186 +9%
Marshall Wace
9
Marshall Wace
United Kingdom
$9.9M -$5.45M -121,698 -38%
BIT
10
BlackRock Institutional Trust
California
$8.59M +$730K +16,309 +11%
WSA
11
Wall Street Associates
California
$8.05M -$31.3K -700 -0.4%
ACA
12
Apis Capital Advisors
New York
$7.29M +$6.42M +143,310 New
Goldman Sachs
13
Goldman Sachs
New York
$6.87M +$3.92M +87,564 +184%
ICRM
14
Insight Capital Research & Management
California
$6.48M -$409K -9,130 -7%
MAA
15
Managed Account Advisors
New Jersey
$6.37M +$893K +19,951 +19%
Northern Trust
16
Northern Trust
Illinois
$6.13M -$35.3K -789 -0.7%
Invesco
17
Invesco
Georgia
$4.87M +$892K +19,925 +26%
Lazard Asset Management
18
Lazard Asset Management
New York
$4.76M +$3.95M +88,120 +1,575%
Deutsche Bank
19
Deutsche Bank
Germany
$4M +$70.2K +1,567 +2%
QI
20
QS Investors
New York
$3.94M +$3.47M +77,513 New
Geode Capital Management
21
Geode Capital Management
Massachusetts
$3.86M +$905K +20,204 +36%
BBA
22
Baker Bros. Advisors
New York
$3.83M – – –
EI
23
EAM Investors
California
$3.81M +$544K +12,147 +19%
B
24
Bailard
California
$3.79M -$761K -17,000 -19%
Bank of New York Mellon
25
Bank of New York Mellon
New York
$3.68M +$232K +5,172 +8%
1
2 3 4 5

ENTA Hedge Fund Activity: Q4 2014 in Review

124 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q4 2014, worth a combined $549M — up 35% from $408M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new ENTA positions and 21 closed out — a net gain of 14 holders — while 36 added to existing stakes and 42 trimmed.

The largest buyer was Apex Capital Management, adding an estimated $24M. The largest seller was Senzar Asset Management, cutting an estimated $23.4M.

  • 124 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q4 2014, up from 111 in Q3 2014.
  • Funds reported $549M of Enanta Pharmaceuticals stock for Q4 2014, up 35% quarter-over-quarter.
  • 35 funds opened new Enanta Pharmaceuticals positions in Q4 2014 and 21 closed out, a net change of +14 holders.
  • The largest Enanta Pharmaceuticals buyer in Q4 2014 was Apex Capital Management, an estimated $24M added.
  • The largest Enanta Pharmaceuticals seller in Q4 2014 was Senzar Asset Management, an estimated $23.4M sold.

Based on aggregated 13F filings for Q4 2014.